CLINICAL TRIALS · PHARMA AND CROs
Precision genetic and epigenetic testing for your trials.
Whole genome sequencing and 930k CpG methylation arrays, run alongside your CRO, to inform patient selection, sharpen drug analytics and understand who responds.
Get in touchWHY IT MATTERS
The right drug can fail with the wrong patients.
Genetic and epigenetic data help explain why some patients respond and others don’t — and who your drug is really for.
trials don’t reach approval
one new drug to approval
- Lack of efficacy and patient heterogeneity are leading causes.
- Conventional biomarkers miss epigenetic drivers of drug response.
- Without multi-omics data, a drug’s best-fit patients stay hidden.
Sources: Sun et al., Acta Pharm Sin B, 2022; DiMasi et al., J Health Econ, 2016.
OUR TESTING
Whole genome sequencing
SNPs, indels and structural variants linked to drug metabolism and treatment response, including CYP450 genes.
930k CpG methylation array
Genome-wide epigenetic patterns as biomarkers of disease state and therapy sensitivity.
Lab to report
From the samples your CRO sends us to trial-ready reports. Studies of 50 to 1,000+ samples, with an 8–10 week turnaround.
APPLICATIONS
Where it helps a trial.
Fewer screen failures
WGS and methylation data that help your CRO pre-screen for the patients most likely to respond.
Sharper PK/PD models
Longitudinal tracking of genetic and epigenetic changes across the trial.
Responsive subgroups
Find the groups that benefit most, to support real-world evidence and companion diagnostics.
PROJECTED IMPACT
Faster, leaner trials.
API connection to Veeva, Oracle and other EDC systems. CLIA/CAP compliant.
Co-branded reports, joint publications and collaborative validation studies.
Try it on 20 samples, at no cost.
A proof-of-concept on samples from your own study before you commit.
Let’s talk about your trial.
Tell us about your study and your CRO, and we’ll suggest how genetic and epigenetic data can support it.